Martin Gertsch

Martin Gertsch

Vorsitzender bei
Artidis AG
61 Jahre
Health Technology
Commercial Services
Consumer Services

Profil

Martin Gertsch is currently the Chairman at Artidis AG, Director at the University of Basel, and Director at Centro Universitário da FEI.
He previously held the position of Vice Chairman at Santhera Pharmaceuticals Holding AG from 2017 to 2021.
He also served as Director at Symetis SA, Evolva Holding SA, Acino International AG, Synthes, Inc., and Acino Pharma AG.
Mr. Gertsch was the Chief Financial Officer at Acino International AG from 2013 to 2014 and at Cell Medica Switzerland AG from 2009 to 2010.
He was also the Head-Finance EMEA Region at Synthes, Inc. and the Vice President & Head-EMEA Finance at DePuy Synthes, Inc. Prior to that, he worked as the Chief Financial Officer at Straumann Holding AG from 2002 to 2006 and as the Chief Financial Officer at ESBATech AG from 2007 to 2009.
Mr. Gertsch started his career as an Audit Engagement Manager at PricewaterhouseCoopers, Inc. from 1986 to 1997.

Aktive Positionen von Martin Gertsch

UnternehmenPositionBeginn
Direktor/Vorstandsmitglied -
Direktor/Vorstandsmitglied -
Vorsitzender -

Ehemalige bekannte Positionen von Martin Gertsch

UnternehmenPositionEnde
SANTHERA PHARMACEUTICALS HOLDING AG Vorsitzender 04.04.2017
ACINO HOLDING AG Finanzdirektor/CFO 14.01.2014
Finanzdirektor/CFO 01.01.2014
Finanzdirektor/CFO 01.01.2010
Finanzdirektor/CFO 01.09.2009
Sehen Sie sich die Erfahrung von Martin Gertsch im Detail an

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Beziehungen

76

Beziehungen ersten Grades

14

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Unternehmensverbindungen

Private Unternehmen14

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Consumer Services

Consumer Services

Health Technology

Commercial Services

Health Technology

Consumer Non-Durables

Health Technology

Health Technology

Health Technology

  1. Börse
  2. Insiders
  3. Martin Gertsch
-40 %: Exklusive Verlängerung
T
:
:
PROFITIEREN SIE JETZT